MRI Contrast Clearance Analysis for Glioma Grading and Genotyping

Glioma Clinical Trial

Official title:

MRI Contrast Clearance Analysis for Prediction of Grading and Genotyping in Gliomas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06018870
• Other study ID #: 2023183
• Status: Recruiting
• Start date: June 1, 2023
• Est. completion date: June 30, 2024

Study information

• Verified date: August 2023
• Source: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
• Contact: Zifan Sang, M.M
• Phone: +8618379873389
• Email: 952034224[@]qq.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Gliomas are the most common primary brain tumor. Gliomas with different grades have different clinical behaviors that determine treatment planning and patient prognosis in clinical practice. In the 2021 World Health Organization (WHO) classification of tumors for the central nervous system, glioma genotyping was considered the most relevant information for neuroradiologists. The isocitrate dehydrogenase (IDH) genotype and 1p/19q codeletion status are two essential molecular markers that divide glioma into three groups: IDH wild-type, IDH mutant with 1p/19q non-codeletion, and IDH mutant with 1p/19q codeletion. MRI contrast clearance analysis (CCA) is based on T1 delayed-contrast subtraction map, Blue/tumor regions in CCA represent efficient clearance of contrast from the tissue (delayed signal<early signal), while red/nontumor regions in CCA represent contrast accumulation (delayed signal>early signal). However, there are not any reports on the role of MRI CCA in glioma grading and genotyping, Thus, We hypothesized that the proportion of blue/red region and their histogram analyses, which could be acquired for predicting IDH genotypes and 1p/19q codeletion in gliomas, and to assess the application of CCA in glioma grading.

Description:

This is a single-center bidirectional cohort study. The subjects of this study were patients diagnosed as glioma by pathological biopsy. Patients with suspicious mass will be performed extra 30 and 60 min after contrast agent application delayed T1-weighted sequences as same as before. Then enter the next experimental stage. (1) Image format conversion; (2) Registration;(3) Subtraction;(4) ROI segmentation;(5) ROI histogram analyses. Histogram parameters of blue and red ROI includes 1st、10th 、90th and 99th percentiles, mean, median, variance, skewness, and kurtosis. Finally, statistical methods were used to determine whether those parameters was statistically significant for IDH mutation status、1p/19q codeletion status and tumor grading.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: June 30, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Patients with brain space -occupying lesions, have not yet undergone antitumor therapy;
• MRI with T1-contract delayed sequence was performed less than 2 weeks before surgery;
• Definite histopathologic diagnosis of glioma.

Exclusion Criteria:

• WHO 1 gliomas and other non-glioma brain tumors;
• Poor image quality and heavy artifact affect the subsequent image processing.

Related Conditions & MeSH terms

• Glioma

Locations

Country	Name	City	State
China	Sang Zifan	Chongqing	Chongqing

Sponsors (1)

Lead Sponsor	Collaborator
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of bule/red ROI	The common vessels morphology in the blue region was undamaged vessel lumens which exists in active tumor, while vessels in the red regions presented different stages of vessel necrosis.	Through study completion, an average of 1 year
Primary	Histogram of bule/red ROI	The bule and red ROI from CCA histogram analysis included1st?10th ?90th and 99th percentiles, mean, median, variance, skewness, and kurtosis.	Through study completion, an average of 1 year